Transcriptomic Study of IBD-associated Colorectal Cancer

September 29, 2021 updated by: MULLER Marie, Central Hospital, Nancy, France

Transcriptiomic Analysis of Inflammatory Bowel Disease-associated Colorectal Cancer. A French Retrospective Study of 26 Cases Identified at the Nancy University Hospital

Chronic inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (CRC) in historical cohorts. The pathways of oncogenesis of these CRCs, which are very different clinically from de novo CRCs, are currently unknown. The aim of our work is to identify specific molecular signatures of CRC occurring in the setting of IBD.

Study Overview

Status

Completed

Conditions

Colorectal Cancer, Genetics of

Intervention / Treatment

Genetic: transcriptomic analysis

Study Type

Observational

Enrollment (Actual)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

>/= 18 years old patient operated on at the Nancy university hospital for IBD associated CRC

Description

Inclusion Criteria:

Person 18 years of age or older
Person with colorectal cancer in the context of IBD
Person who has received complete information on the organization of the research and who has signed an informed consent
Person affiliated to a social security plan or beneficiary of such a plan.

Exclusion Criteria:

Person referred to in articles L. 1121-5, L. 1121-7 and L1121-8 of the public health code:
Pregnant woman, parturient or nursing mother
Minor (not emancipated)
Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
Person of legal age who is unable to express his or her consent
Person deprived of liberty by a judicial or administrative decision, persons subject to psychiatric care under articles L. 3212-1 and L. 3213-1.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IBD associated CRC oncogenesis Time Frame: 1 year	Percentage of gene expression variation in CRC tumor tissue samples in the following groups patients with CRC and IBD	1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Hospital, Nancy, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2010

Primary Completion (ACTUAL)

January 1, 2021

Study Completion (ACTUAL)

January 1, 2021

Study Registration Dates

First Submitted

September 19, 2021

First Submitted That Met QC Criteria

September 19, 2021

First Posted (ACTUAL)

September 29, 2021

Study Record Updates

Last Update Posted (ACTUAL)

October 7, 2021

Last Update Submitted That Met QC Criteria